An interventional study of Cyclic single channel neuromuscular stimulation and Electromyogram-triggered 4 channel neuromuscular stimulation in Moderate Arm Paresis and Ischemic Stroke, sponsored by MED-EL Elektromedizinische Geräte GesmbH. Recruiting at 3 sites in Austria. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by MED-EL Elektromedizinische Geräte GesmbH · Not applicable, Interventional, and Treatment
This study will compare two treatments that may help participants recover after having suffered from stroke. Persons who experience weakness or paralysis of their arms/hands will be randomly placed in one of two groups. Each receives treatment five times a week for three weeks. One group will be treated with electrostimulation following a cyclic pattern (control treatment), the other group will be treated with electrostimulation triggered by nerve signals (i.e. stimulation starts when they deliberately try to move their arm (investigational treatment). Before and after the three weeks and additionally 12 weeks later, the ability to move the arm and hand will be documented with standardized tests.
2,612 studies on the registry are indexed under Ischemic Stroke; 971 are open to participants now.
This study's planned enrollment of 44 is below the median of 120 across 1,776 interventional studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →MED-EL Elektromedizinische Geräte GesmbH is the lead sponsor of 35 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single channel cyclic neuromuscular stimulation used for the rehabilitation of moderate arm paresis
Device: Cyclic single channel neuromuscular stimulation
EMG-triggered, four channel neuromuscular stimulation used for the rehabilitation of moderate arm paresis
Device: Electromyogram-triggered 4 channel neuromuscular stimulation
Cyclic single channel neuromuscular stimulation is used to trigger repetitive muscular contractions
EMG-MES provides biofeedback by using electromyographic signals to trigger muscular contractions
Also known as: EMG-MES
Stroke Impact Scale (SIS) subscale Recovery
Scores between 0 and 100, higher meaning a better outcome
Time frame: pre-intervention to 3 weeks
Stroke Impact Scale (SIS), subscale strength
Scores between 0 and 100, higher meaning a better outcome
Time frame: pre-intervention to 3 weeks
Stroke impact scale (SIS) subscale Activities of Daily Living (ADL) / Instrumental Activities of Daily Living (IADL)
Scores between 0 and 100, higher meaning a better outcome
Time frame: pre-intervention to 3 weeks
Stroke impact scale (SIS) subscale mobility
Scores between 0 and 100, higher meaning a better outcome
Time frame: pre-intervention to 3 weeks
Stroke impact scale (SIS) subscale hand function
Scores between 0 and 100, higher meaning a better outcome
Time frame: pre-intervention to 3 weeks
Fugl-Meyer Assessment - upper extremity (FMA-UE)
Scores between 0 and 100, higher meaning a better outcome
Time frame: pre-intervention to 3 weeks
Action Research Arm Test (ARAT)
Scores between 0 and 57, higher meaning a better outcome
Time frame: pre-intervention to 3 weeks
Safety assessment
Assessment of device related adverse events
Time frame: through study completion, an average of 15 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jan 2028, 29 months after the start.
Of 81 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 29 months is above that.
Counting every sponsor, half of 653 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MED-EL Elektromedizinische Geräte GesmbH →